Sanofi launches blood glucose monitor with estimated HbA1c
Sanofi has launched the first self-monitoring device that provides estimates of the HbA1c value, a key indicator for long-term glucose control.
The company claims its MyStar Extra® blood glucose monitoring device may help people with diabetes better understand the meaning of their test results in the context of overall treatment goals.
Several extra features of the device may help people with diabetes stay motivated and engaged in managing their insulin therapy, Sanofi said.
Diabetes blogger Chris Aldred, who is behind Twitter personality @grumpy_pumper, said: “Living with Type 1 diabetes is hard work with no time off. It’s a constant balancing act between ensuring I have the correct amounts of insulin to keep my blood glucose at safe levels. This takes motivation.
“For me to stay motivated in my diabetes management I need accurate and consistent data from my blood glucose device. Without this, I am unable to make the informed decisions that I need to manage my diabetes the way that I want to. Next to insulin, reliable data from my blood glucose device is the most important tool that I have to manage my diabetes. I welcome any new technologies that may support me stay motivated and engaged.”
One of the parameters used to assess the level of glycaemic control in people with diabetes is the HbA1c (haemoglobin A1c) value. The HbA1c value reflects average glucose levels over the previous three months and is therefore regarded as an indicator for long term glucose control.
Until now, HbA1c levels were obtained through a laboratory test which patients receive on average once or twice a year, but now MyStar Extra® can provide an HbA1c estimate. The device uses unique algorithms to provide estimates of HbA1c. While this does not replace the laboratory test, it provides more immediate feedback on therapy progress.
In addition to the HbA1c estimate, MyStar Extra® calculates a three-day fasting plasma glucose average (FPG) and FPG trends. For people with diabetes who find it challenging to follow treatment regimes, three-day fasting averages simplify access to practical glucose information. FPG values measure the blood glucose concentration in a blood sample after an overnight fast.
Three-day FPG averages are commonly used to titrate basal insulin, one of the most used treatment approaches in type 2 diabetes. The innovative technology of MyStar Extra®, simplifies diabetes management through using smart technology to produce immediate feedback.
Becky Reeve, Head of Professional Relations, Sanofi UK, said: “The device provides the personal glucose information people with diabetes need in a simple form, enabling them to manage their diabetes and track their long-term therapy success. This is what smart technology is all about: MyStar Extra® helps patients understand control of their diabetes better, and helps to motivate them to stick to their recommended therapy.”